Published in Oncoimmunology on April 16, 2014
Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology (2014) 2.30
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Front Immunol (2015) 1.12
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology (2015) 1.07
Immunogenic cell death inducers as anticancer agents. Oncotarget (2014) 1.05
Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology (2015) 1.02
Combinatorial strategies for the induction of immunogenic cell death. Front Immunol (2015) 0.98
The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization. Oncotarget (2015) 0.95
The oncolytic peptide LTX-315 triggers necrotic cell death. Cell Cycle (2015) 0.91
Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapy. Oncotarget (2015) 0.89
Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy? Oncoimmunology (2015) 0.86
Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer. Oncoimmunology (2016) 0.82
Immunosurveillance in esophageal carcinoma: The decisive impact of regulatory T cells. Oncoimmunology (2015) 0.78
Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy. Oncoimmunology (2015) 0.77
Improvement of immunogenic chemotherapy by STAT3 inhibition. Oncoimmunology (2015) 0.76
Yet another pattern recognition receptor involved in the chemotherapy-induced anticancer immune response: Formyl peptide receptor-1. Oncoimmunology (2016) 0.76
Trial Watch: Proteasomal inhibitors for anticancer therapy. Mol Cell Oncol (2014) 0.75
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer (2006) 11.49
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ (2011) 9.44
Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol (2010) 9.06
Humanized mice in translational biomedical research. Nat Rev Immunol (2007) 8.83
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Immunological aspects of cancer chemotherapy. Nat Rev Immunol (2008) 6.61
Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59
Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol (2006) 6.13
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62
Molecular mechanisms of cisplatin resistance. Oncogene (2011) 5.20
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32
Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73
The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ (2009) 3.44
Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 3.26
Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene (2009) 2.74
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 2.72
Cell death assays for drug discovery. Nat Rev Drug Discov (2011) 2.51
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J (2012) 2.45
The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ (2008) 2.01
Chemotherapy induces ATP release from tumor cells. Cell Cycle (2009) 1.83
Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene (2010) 1.75
Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ (2013) 1.64
Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur J Immunol (2013) 1.63
Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med (2012) 1.63
Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res (2011) 1.62
Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep (2012) 1.45
Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ (2013) 1.39
Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology (2013) 1.35
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2012) 1.33
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2013) 1.31
CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. Cancer Res (2013) 1.22
Trial watch: Cardiac glycosides and cancer therapy. Oncoimmunology (2013) 1.21
Enlightening the impact of immunogenic cell death in photodynamic cancer therapy. EMBO J (2012) 1.14
Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ (2013) 1.12
Adoptive immunotherapy of newly induced murine sarcomas. Cancer Res (1985) 1.12
Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39. Oncoimmunology (2012) 1.12
NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. Blood (2012) 1.09
ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. Oncoimmunology (2013) 1.01
Crosstalk between ER stress and immunogenic cell death. Cytokine Growth Factor Rev (2013) 0.91
Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects. Oncoimmunology (2012) 0.91
Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy. Oncoimmunology (2013) 0.84
Immune effects of 5-fluorouracil: Ambivalence matters. Oncoimmunology (2013) 0.83
Immunogenic tumor cell death induced by chemoradiotherapy in a clinical setting. Oncoimmunology (2013) 0.81
Non-apoptotic routes to defeat cancer. Oncoimmunology (2012) 0.80
Dacarbazine mediate antimelanoma effects via NK cells. Oncoimmunology (2013) 0.80
SEPTACIDIN, A NEW ANTITUMOR AND ANTIFUNGAL ANTIBIOTIC PRODUCED BY STREPTOMYCES FIBRIATUS. Antimicrob Agents Chemother (Bethesda) (1963) 0.78
Immune ambivalence: The schizophrenic bleomycin. Oncoimmunology (2013) 0.77